7,718.60

-29.11

-0.38%

53,414.25

-271.86

-0.51%

26,506.99

-77.11

-0.29%

2,975.65

+7.38

+0.25%

14.53

+0.21

+1.47%

4,476.60

-63.30

-1.39%

79,636.50

-1,584.69

-1.95%

Crude Oil Oct 26

91.48

+0.18

+0.20%

Swiss - Delayed Quote CHF

Roche Holding AG (ROP.SW)

Get top stock picks

357.00 +0.50 (+0.14%)

At close: September 4 at 5:31:48 PM GMT+2

Get top stock picks

Loading Chart for ROP.SW

Chart Range Bar

Interval:

In partnership with ChartIQ

Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?

Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point

IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point

Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry

Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry

Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis

TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis

Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion

Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion

Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test

Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test

BioNTech Kills a Cancer Trial Roche Helped Build

BioNTech Kills a Cancer Trial Roche Helped Build

Mobilize your Website

View Site in Mobile | Classic

Share by: